🇺🇸 Intranasal calcitonin in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Arthralgia — 1 report (10%)
2. Arthritis Infective — 1 report (10%)
3. Cellulitis — 1 report (10%)
4. Compression Fracture — 1 report (10%)
5. Haematocrit Decreased — 1 report (10%)
6. Haemoglobin Decreased — 1 report (10%)
7. Incision Site Erythema — 1 report (10%)
8. Influenza Like Illness — 1 report (10%)
9. Intestinal Dilatation — 1 report (10%)
10. Presyncope — 1 report (10%)

Source database →

Frequently asked questions

Is Intranasal calcitonin approved in United States?

Intranasal calcitonin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Intranasal calcitonin in United States?

Université de Montréal is the originator. The local marketing authorisation holder may differ — check the official source linked above.